500 results on '"Romaguera J"'
Search Results
52. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center.
53. Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience.
54. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study.
55. P549 HPV infection in anogenital specimens of Puerto Rican women: Comparison with cervical cytology results
56. Identification of supportive care needs in a sample of Puerto Rican cancer patients with the Supportive Care Needs Survey-34 (SCNS-34)
57. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin’s lymphomas
58. Activity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study
59. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma
60. Early (18F) fluoro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin’s lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C)
61. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator’s choice therapy
62. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
63. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
64. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M. D. Anderson experience in 40 patients
65. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States from 1975 to 2003
66. Increased toxicity associated with delayed clearance of methothrexate (MTX) in patients with lymphoma receiving high-dose MTX
67. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy
68. Risk factors for severe anemia requiring red blood cell transfusions in lymphoma patients receiving chemotherapy
69. Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy
70. Predictive value for survival of a risk model of two serological markers, beta-2-microglobulin (B2M) and lactic dehydrogenase (LDH), in diffuse large cell lymphoma (DLCL)
71. A phase II study of HCVIDDOXIL alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma
72. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).
73. Lifestyles and Health Factors Affecting Dyspareunia in a Sample of Pre and Post Menopausal Puerto Rican Women
74. Gallium Scan after the second and fourth chemotherapy cycle predicts clinical outcomes in aggressive non-Hodgkin’s lymphomas
75. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease
76. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL)
77. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study
78. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL)
79. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma
80. Fetal Lung Maturation in Congenital Diaphragmatic-hernia
81. Infusional Vinorelbine in Relapsed or Refractory Lymphomas
82. The glucose to insulin ratio (GIR) is useful predicting insulin resistance (IR) only in obese, but not non-obese, women with hyperandrogenism (HA)
83. Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases
84. Perceptions regarding oral contraceptive use in hispanic adolescents
85. Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma
86. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
87. Ninety-Six-Hour Paclitaxel Infusion with Mitoxantrone and Ifosfamide/Mesna and Consolidation with ESHAP for Refractory and Relapsed Non-Hodgkin's Lymphoma
88. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
89. Use of the International Prognostic Index and the Tumor Score to Detect Poor-Risk Patients with Primary Mediastinal Large B-Cell Lymphoma: A Study of 37 Previously Untreated Patients
90. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.
91. Paclitaxel (Taxol®) for the treatment of lymphoma
92. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
93. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
94. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma
95. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
96. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
97. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
98. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: A phase II study
99. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
100. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.